

Distribution study of atorvastatin and its metabolites in rat tissues using combined information from UHPLC/MS and MALDI-Orbitrap-MS imaging

Robert Jirásko, Michal Holčapek, Martin Kuneš and Aleš Svatoš




Fig. S1. Experimental setup used for the sublimation deposition of matrices




Fig. S2. Calibration curve of AT with the normalization to AT-d5. Calibration curve error bars represent the standard deviations of three different measurements (Table S1)

Table S1. List of AT standard solutions used for UHPLC/MS quantitation study, their concentrations and experimental values of particular ratios of UHPLC/MS peak areas for AT and its internal standard EIC_{AT}/EIC_{IS}

Dilution of AT stock solution	Concentration [ng/ μ l]	Ratio of UHPLC/MS peak area			EIC_{AT}/EIC_{IS}
		analysis 1	analysis 2	analysis 3	average value
5000x	0.060	0.301	0.303	0.300	0.301 ± 0.001
3000x	0.100	0.438	0.431	0.434	0.434 ± 0.003
2000x	0.149	0.533	0.571	0.524	0.543 ± 0.020
1000x	0.299	1.170	1.130	1.110	1.137 ± 0.025
700x	0.427	2.070	2.190	2.090	2.117 ± 0.052
500x	0.598	2.890	2.800	2.800	2.830 ± 0.042
300x	0.997	4.320	4.090	3.970	4.127 ± 0.145
100x	2.990	12.290	12.920	12.400	12.537 ± 0.275

Table S2. Experimental data of UHPLC/MS quantitation study including description of measured rat samples, particular ratios of UHPLC/MS peak areas for AT and its internal standard EIC_{AT}/EIC_{IS} and average of AT concentrations including three sample injections calculated based on the calibration curve

rat samples	Ratio of UHPLC/MS peak area EIC_{AT}/EIC_{IS}				AT concentration [mg/kg] / [mg/l]
	analysis 1	analysis 2	analysis 3	average value	
liver, slice 1 (7.1 mg)	1.949	1.973	2.147	2.023 ± 0.088	19.78 ± 0.89
liver, slice 2 (9.5 mg)	2.660	2.847	2.707	2.738 ± 0.080	20.17 ± 0.60
liver, slice 3 (9.1 mg)	2.558	2.667	2.674	2.633 ± 0.053	20.24 ± 0.42
serum	6.438	6.252	5.895	6.195 ± 0.226	0.44 ± 0.02
feces 202 mg (1000x diluted)	2.602	2.502	2.684	2.596 ± 0.074	898 ± 25
urine	< LOD	< LOD	< LOD	-	< LOD